Please assess the completion status of the following clinical trial:

Trial Title: Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ages 40-65 years~2. Antiretroviral use (ART) \>12 months and HIV viral load \<100 copies/mL~3. VAT\> 110cm2~Exclusion Criteria:~1. Antihypertensive use including, ACE Inhibitor, ARB, MR blockade, diuretic, potassium (K) supplementation; or BP\>140/90 mmHg. Stable use (\>3 months) of beta-blockers or calcium channel blockers (CCB) (except verapamil) is allowed.~2. Unstable statin use \<12 months. Stable use (\>12 months) is allowed.~3. Use of full dose ritonavir, nelfinavir, clarithromycin, and other strong inhibitors of CYP3A4, as well as CYP3A4 inducers.~4. Continuous oral steroid use (equivalent to prednisone \> 5 mg daily) within the last 3 months.~5. Uncontrolled diabetes requiring insulin and/or HbA1c \> 7.5%.~6. Creatinine (Cr) \> 1.5 mg/dL or estimated GFR\<60 mL/min/1.73m2.~7. K \> 5.5 mEq/L.~8. Hemoglobin \< 10 g/dL.~9. Known liver disease or ALT \>3x ULN.~10. History of congestive heart failure, stroke, myocardial infarction, or known coronary artery disease.~11. Pregnant, actively seeking pregnancy or breastfeeding.~12. Estrogen, progestin derivative, or other sex steroid use within last 3 months. Stable physiologic testosterone replacement (\> 3 months) is acceptable.~13. Current bacterial or other infections.~14. Active substance abuse.~15. Significant radiation exposure over the course of the year prior to randomization (e.g., radiation therapy, PCI, catheter ablation of arrhythmia) within 12 months of randomization.~16. Previous reaction or contraindication to iodine-containing contrast media and gadolinium.~17. Coronary artery luminal narrowing \>70% on coronary CTA.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Eplerenone (Type: EXPERIMENTAL): Eplerenone 50 mg twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months
- Placebo (Type: PLACEBO_COMPARATOR): Placebo twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).